Velocity Clinical Research, a multi-specialty clinical sites business, has expanded in Europe, adding five sites in Poland following the acquisition of KO-MED Centra Kliniczne, and two sites in Germany with the acquisition of The Pulmonary Research Institute.
 
Velocity is accelerating growth across Europe with 17 locations in the UK, Poland and Germany. The company is now one of the largest site organizations in Europe in addition to being among the largest sites business in the U.S.
 
Dominic Clavell, European General Manager for Velocity, said, “Velocity is building an integrated network of sites and we have the size and scale where we can recruit enough patients, either for entire studies or contribute significantly to country targets in Europe. This dramatically speeds up site start-up times, saving considerable time for CROs and Sponsors.”   
 
The acquisition of KO-MED is Velocity’s first foray into oncology research, which accounts for approximately 40-50% of clinical trials globally. 
 
The Pulmonary Research Institute leads research in bronchial asthma, bronchiectasis and pulmonary fibrosis. 
 
The new sites join Velocity’s existing four sites in Germany, one in Poland and five in the UK. Velocity has almost 100 locations globally and access to more than 220 principal investigators and one million patients. 
 
Velocity’s sites are fully integrated via a centralized infrastructure and common technology, allowing for streamlined patient enrollment and consistent, high-quality data delivery.